BioMarin CFO granted options and RSUs

BioMarin Pharmaceutical EVP and CFO Brian Mueller reported routine equity compensation and related tax withholding.

Rhea-AI Filing Summary

BioMarin Pharmaceutical EVP and CFO Brian Mueller reported routine equity compensation and related tax withholding. He received a stock option grant for 44,600 shares of common stock at an exercise price of $57.43 per share, vesting partly from March 16, 2027 through monthly installments until 2031. He was also granted 18,740 shares of common stock as restricted stock units with no purchase price.

To cover tax obligations on a prior vesting event, 9,945 shares of common stock were withheld at $58.51 per share, a non‑market disposition. Following these transactions, Mueller directly holds 125,431 common shares and the new option for 44,600 shares.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Mueller Brian

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy Common Stock)	44,600	$0.00	$0.00
Grant/Award	Common Stock	18,740	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	9,945	$58.51	$582K

Holdings After Transaction: Stock Option (Right to Buy Common Stock) — 44,600 contracts (Direct); Common Stock — 125,431 shares (Direct)

Footnotes (3)

1. F1. Restricted stock units granted March 16, 2026. Price not applicable.
2. F2. The Reporting Person's direct holdings have been adjusted by two shares to correct a previous clerical error.
3. F3. Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.

FAQ

What new stock option grant did BioMarin (BMRN) CFO Brian Mueller receive?

Brian Mueller received a stock option grant for 44,600 shares of BioMarin common stock at an exercise price of $57.43 per share. The option vests over time starting March 16, 2027 and expires on March 15, 2036.

Did the BioMarin (BMRN) CFO receive additional BioMarin common stock directly?

Yes. Brian Mueller was granted 18,740 shares of BioMarin common stock in the form of restricted stock units. These units were granted on March 16, 2026 and carry no purchase price, functioning as equity-based compensation from the company.

Why were 9,945 BioMarin (BMRN) shares disposed of in this Form 4 filing?

The 9,945 shares of BioMarin common stock were withheld at $58.51 per share to satisfy tax liabilities. This disposition is coded F, meaning it covered exercise price or taxes, and does not represent an open-market sale by the CFO.

How many BioMarin (BMRN) shares does CFO Brian Mueller own after these transactions?

After these transactions, Brian Mueller directly holds 125,431 shares of BioMarin common stock. In addition, he holds a newly granted stock option covering 44,600 shares, providing potential future ownership if he chooses to exercise it.

What is the vesting schedule for the new BioMarin (BMRN) stock option granted to the CFO?

The option grant vests 12/48ths on March 16, 2027, with the remaining 1/48th vesting on the 16th of each subsequent month. This structure gradually delivers full vesting before the option’s expiration on March 15, 2036.

Are the transactions in this BioMarin (BMRN) Form 4 mainly compensation-related?

Yes. The filing shows a stock option grant, a restricted stock unit grant, and tax withholding of 9,945 shares. These are typical equity compensation and tax events for an executive, rather than discretionary open-market purchases or sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 08:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mueller Brian

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		F		9,945	D	$58.51	106,691	D
Common Stock	03/16/2026		A		18,740	A	$0(1)	125,431(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$57.43	03/16/2026		A		44,600		03/16/2027(3)	03/15/2036	Common Stock	44,600	$0	44,600	D

Explanation of Responses:

1. Restricted stock units granted March 16, 2026. Price not applicable.

2. The Reporting Person's direct holdings have been adjusted by two shares to correct a previous clerical error.

3. Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.